Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30376230 | 1.00 | LPL (0.47) | LPLLIPGTRPV4ESR2ROCK1 | |
| SCHEMBL30375876 | 0.87 | LPL (0.47) | LPLLIPGESR2ROCK1EGFR | |
| SCHEMBL1514603 | 0.87 | LPL (0.47) | LPLLIPGESR2ROCK1EGFR | |
| SCHEMBL12327209 | 0.85 | LIPG (0.44) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL422959 | 0.82 | ESR2 (0.42) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL2656823 | 0.82 | LPL (0.41) | LPLLIPGESR2ROCK1CYP11B1 | |
| SCHEMBL20639735 | 0.81 | LPL (0.40) | LPLLIPGTRPV4ESR2ROCK1 | |
| SCHEMBL18339421 | 0.81 | LPL (0.40) | LPLLIPGTRPV4ESR2ROCK1 | |
| SCHEMBL14830981 | 0.81 | ESR2 (0.41) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL748654 | 0.81 | TRPV4 (0.43) | LPLLIPGTRPV4ESR2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-12427154-B2 | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | INCYTE HOLDINGS CORPORATION (US) | 2025-09-30 | — | — | US | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| US-12234241-B2 | Imidazotriazine thiobenzamide derivative, and preparation method and application thereof | Yunbaiyao Zhengwu Science and Technology (Shanghai) Co., Ltd. (CN) | 2025-02-25 | — | — | US | disclosed |
| EP-4509500-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | Sichuan Huiyu Pharmaceutical Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| WO-2009143211-A2 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | INCYTE CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143211-A2 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | INCYTE CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090291956-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | INCYTE CORPORATION | 2009-11-26 | — | — | US | disclosed |
| US-20090291956-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | INCYTE CORPORATION | 2009-11-26 | — | — | US | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-05 | — | — | US | disclosed |
| US-7459564-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1841504-A2 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | Brystol-Myers Squibb Company (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006076575-A2 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427154-B2 | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | ABL1, MET, ABL2 | LPL 4814/4885LIPG 4369/4885TRPV4 3339/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | LPL 2197/4885LIPG 4125/4885TRPV4 1449/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | LPL 178/4885LIPG 249/4885TRPV4 2004/4885 |
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | TFPI, F3, F12 | LPL 1371/4885LIPG 266/4885TRPV4 3540/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | LPL 3327/4885LIPG 2261/4885TRPV4 3791/4885 |
| US-20090291956-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | ABL1, MET, ABL2 | LPL 4814/4885LIPG 4369/4885TRPV4 3339/4885 |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, F3, F12 | LPL 1371/4885LIPG 266/4885TRPV4 3540/4885 |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | HDAC1, HDAC11, HDAC5 | LPL 3146/4885LIPG 3963/4885TRPV4 1951/4885 |
| US-12234241-B2 | Imidazotriazine thiobenzamide derivative, and preparation method and application thereof | TPMT, SLC5A11, DPYD | LPL 4804/4885LIPG 4833/4885TRPV4 1110/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | LPL 2661/4885LIPG 3389/4885TRPV4 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.